Articles

1801-1820 of 2112 < first | | | last >
  • Controlling Crystallization through Modeling

    CFD modeling and particle population control are key to improving processes and product quality at the crystallizer, and further downstream.

    Kumar Dhanasekharan, Ph.D., Consulting Team Leader, Fluent, Inc., and Terry Ring, Ph.D., Professor, Dept. of Chemical Engineering, University of Utah
    08/05/2005
  • "What's In It for Me?" Taking PAT to the Executive Suite, Part 1

    In this audio interview at his offices in Dublin, Paraic O'Toole, CEO of Automsoft, talks about the issues affecting PAT's future. Instead of thinking "technology," he says, corporate executives should view PAT as a tool to improve share prices and profitability. PhRMA could play a far more active role in educating the top brass, and FDA support, at the Commissioner level, would speed PAT's adoption.

    Agnes Shanley, Editor in Chief
    08/04/2005
  • "What's In It for Me?" Taking PAT to the Executive Suite, Part 2

    In this audio interview at his offices in Dublin, Paraic O'Toole, CEO of Automsoft, talks about the issues affecting PAT's future. Instead of thinking "technology," he says, corporate executives should view PAT as a tool to improve share prices and profitability. PhRMA could play a far more active role in educating the top brass, and FDA support, at the Commissioner level, would speed PAT's adoption.

    Agnes Shanley, Editor in Chief
    08/04/2005
  • Applying PAT Principles to Blister Packaging

    FEA Modeling, 3-D Scanning, and SEM are all part of a “right first time” approach to pharmaceutical packaging.

    Peter J. Schmitt, President, Montesino Associates, LLC
    08/01/2005
  • BMS, CBS Focus on PAT to Save Biopharm Big Bucks

    In September, a new Center for Bioanalytical Sciences will start up, involving Bristol-Myers Squibb Co., Dublin City University and the National University of Ireland, Galway. BMS predicts the technologies being developed could reduce biopharmaceutical production costs by $80 million per year for a typical medium to large processing line.

    Agnes Shanley, Editor in Chief
    07/29/2005
  • Plug and Play PAT, Anyone?

    A common user interface, and “out of the box” software will be essential to driving PAT in the pharmaceutical industry, say Pfizer’s control and IT experts Velumani Pillai and Martin Warman. They’re developing a template for IT requirements and seek input from vendors and other users.

    Velumani Pillai and Martin Warman, Pfizer, Inc.
    07/28/2005
  • Ending the Paper Chase

    Pioneers are taking e-notebooks beyond the R&D lab.

    Angelo De Palma, Ph.D., Contributing Editor
    07/27/2005
  • On the Trail of the Celtic Tiger

    Ireland’s pharmaceutical base faces stiff competition from lower cost centers, but it’s clearly on the leading edge.

    Agnes Shanley, Editor in Chief
    07/22/2005
  • Grooming the Celtic Tiger for Drugmaking Dominance

    In this audio interview, Niall O'Donnellan, manager of life sciences and chemicals at Enterprise Ireland discusses developments in pharmaceutical manufacturing on the Emerald Isle. Enterprise Ireland is the government agency charged with stimulating entrepreneurship and the development of new companies in Ireland.

    Agnes Shanley, Editor in Chief
    07/22/2005
  • It's a Small(er) World

    Nanotechnology developments illustrate the potential of miniaturization to transform the pharmaceutical industry.

    Gregg Carlstrom, PharmaManufacturing.com Assistant Editor
    07/21/2005
  • RFID: Where Do We Stand?

    RFID has been a hot topic of conversation, thanks to the mega-retailers, the DOD and the FDA. But actual adoption of the technology has been tepid at best.

    Bert Moore, AIM Global
    07/14/2005
1801-1820 of 2112 < first | | | last >